Extended-release combination tablet containing DPP-4 inhibitor and biguanide, used in type 2 diabetes management. Procured by hospitals, clinics, and pharmacies for outpatient and inpatient care. Manufactured by pharmaceutical firms and distributed through wholesale networks to healthcare providers treating endocrine disorders.